The results of a clinical study carried out by ALYATEC for the American pharmaceutical company Regeneron Pharmaceuticals were presented at the annual meeting of the American Academy of Allergy, Asthma and Immunology (26th February to 1st March 2021).
On this occasion, Prof. de Blay, principal investigator of the study and medical expert of ALYATEC, spoke to Medscape. In this interview, he reviews the progress of the clinical trial and shares his impressions about these very promising results.
The article can be read here: Novel Agent Shows Promise Against Cat Allergy
